申请人:OHIO STATE INNOVATION FOUNDATION
公开号:US11312686B2
公开(公告)日:2022-04-26
Disclosed herein are compounds, 3,4,6,8-substituted-2-([1′-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
本文公开的化合物是3、4、6、8-取代的-2-([1′-联苯]-4-基)喹啉类似物,它们是具有改进的药代动力学特性的二氢烟酸脱氢酶(DHODH)抑制剂。所公开的化合物可用于治疗各种疾病,其中抑制 DHODH 在临床上是有用的,这些疾病包括癌症,如血液肿瘤,包括急性髓性白血病(AML);移植物抗宿主疾病;自身免疫性疾病;以及与 T 细胞增殖相关的疾病。所公开的化合物在口服给药时可表现出翻转动力学,即吸收率而非消除率主导药代动力学的药代动力学。所公开的化合物可以表现出持续的药代动力学特征,而不是立即释放的特征。本摘要旨在作为在特定技术领域进行搜索的扫描工具,并非对本公开内容的限制。